Shots:
- The global vaccine market, valued at $72.8B in 2025 and projected to reach $115.8B by 2033, continues to benefit from expanding immunization coverage, growing awareness of infectious disease prevention, and innovation across RSV, pneumococcal, HPV, and mRNA vaccines. Pfizer’s Prevnar Family led the market with $6.49B in revenue, followed by Merck’s Gardasil/Gardasil 9 ($5.23B) and GSK’s Shingrix ($4.85B)
- Adult vaccination programs, RSV prevention strategies, and next-generation vaccine technologies are emerging as key growth drivers, with strong commercial momentum observed across pneumococcal, meningococcal, shingles, and RSV vaccine portfolios
- Despite remaining among the world’s top-selling vaccines, COVID-19 vaccine revenues continued to normalize in 2025 as the market shifted from pandemic-driven demand toward routine seasonal immunization and targeted booster programs
The table compares the top five selling vaccines by global sales in 2024 and 2025, highlighting shifts in market leadership and changes in product rankings between the two years.
The global vaccine market witnessed a notable leadership shift in 2026 as Pfizer’s Prevnar franchise overtook Merck’s Gardasil/Gardasil 9 to become the highest-revenue vaccine portfolio. The change reflects sustained demand for adult pneumococcal vaccination, driven by the continued expansion of Prevnar 20, while Gardasil experienced slower growth following years of exceptional momentum. Meanwhile, Shingrix retained its position among the top three vaccines, underscoring the resilience of the adult immunization market. COVID-19 vaccines Comirnaty and Spikevax remained in the top five despite continued post-pandemic demand normalization, highlighting the market’s transition from pandemic-driven sales to a broader focus on routine and preventive vaccination.
20. Fluarix/FluLaval
Total Revenue: $0.4B
Company: GSK
First Approved: US (Dec 14, 2012), EU (Dec 12, 2018)
Indications Approved: Influenza
- Fluarix and FluLaval are quadrivalent inactivated influenza vaccines developed to protect against seasonal influenza by inducing antibody responses against influenza A and B virus strains recommended for each flu season
- The vaccines contain hemagglutinin antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages and are indicated for active immunization against influenza in children and adults across a broad range of age groups, depending on regional approvals
- In 2025, Fluarix/FluLaval generated revenue of $0.40B, reflecting a 21.57% decline compared to $0.51B in 2024. The decrease was primarily attributed to lower demand in both the U.S. and international markets, resulting in reduced seasonal influenza vaccine sales during the year.
19. M-M-R II
Total Revenue: $0.48B
Company: Merck
First Approved: US (1978), EU (N/A)
Indications Approved: Measles, Mumps, Rubella
- M-M-R II is a live attenuated combination vaccine developed to protect against measles, mumps, and rubella (MMR) by inducing both humoral and cellular immune responses against the three viral pathogens
- The vaccine contains live attenuated strains of measles (Enders’ Edmonston), mumps (Jeryl Lynn), and rubella (Wistar RA 27/3) viruses and is indicated for active immunization against measles, mumps, and rubella in children, adolescents, and adults according to recommended vaccination schedules
- In 2025, M-M-R II generated revenue of $0.48B, representing a 4.34% increase compared to $0.46B in 2024. Growth was primarily driven by higher sales in the US, largely reflecting increased demand and higher net pricing, partially offset by lower demand in certain international markets
18. Menveo
Total Revenue: $0.54B
Company: GSK
First Approved: US (Feb 19, 2010), EU (Mar 15, 2010)
Indications Approved: Meningitis
- Menveo is a quadrivalent meningococcal conjugate vaccine developed to prevent invasive meningococcal disease (IMD) by inducing T-cell–dependent immune responses against Neisseria meningitidis serogroups A, C, W, and Y
- The vaccine contains oligosaccharides from meningococcal serogroups A, C, W, and Y conjugated to the CRM197 carrier protein and is indicated for active immunization against invasive meningococcal disease in children, adolescents, and adults across multiple age groups, depending on regional approvals
- In 2025, Menveo generated revenue of $0.54B, representing a 12.50% increase compared to $0.48B in 2024. Growth was primarily driven by higher overall sales across key markets
17. Priorix
Total Revenue: $0.57B
Company: GSK
First Approved: US (Jun 03, 2022), EU (May 25, 2012)
Indications Approved: Measles Prophylaxis, Mumps Prophylaxis, Rubella Prophylaxis
- Priorix is a live attenuated combination vaccine developed to protect against measles, mumps, and rubella (MMR) by inducing both humoral and cellular immune responses against the three viral pathogens
- The vaccine contains attenuated strains of measles (Schwarz), mumps (RIT 4385 derived from the Jeryl Lynn strain), and rubella (Wistar RA 27/3) viruses and is indicated for active immunization against measles, mumps, and rubella in children, adolescents, and adults according to regional immunization schedules
- In 2025, Priorix generated revenue of $0.57B, representing a 42.5% increase compared to $0.40B in 2024. Growth was primarily driven by higher overall sales across key markets
16. RotaTeq
Total Revenue: $0.67B
Company: Merck & Co.
First Approved: US (Feb 03, 2006), EU (Jun 27, 2006)
Indications Approved: Rotavirus Vaccine
- RotaTeq is a live, oral pentavalent rotavirus vaccine developed to prevent rotavirus gastroenteritis by inducing protective immune responses against the most common rotavirus serotypes responsible for severe diarrhoea in infants and young children
- The vaccine contains five live reassortant rotaviruses representing G1, G2, G3, G4, and P1A serotypes and is indicated for the prevention of rotavirus gastroenteritis in infants, administered as a three-dose oral series beginning in early infancy
- In 2025, RotaTeq generated revenue of $0.67B, reflecting a 5.63% decline compared to $0.71B in 2024. The decrease was primarily attributed to lower sales in both the US and international markets, resulting in reduced overall demand for the vaccine
15. Infanrix/Pediarix
Total Revenue: $0.7B
Company: GSK
First Approved: US (Jul 08, 2003), EU (Oct 23, 2000)
Indications Approved: Diphtheria, Tetanus, Pertussis, Polio, Hepatitis B, Haemophilus Influenza Type B
- Infanrix and Pediarix are combination pediatric vaccines developed to protect against multiple infectious diseases by inducing immune responses against diphtheria, tetanus, pertussis, hepatitis B, and poliovirus antigens
- Infanrix is a diphtheria, tetanus, and acellular pertussis (DTaP) vaccine, while Pediarix combines DTaP with hepatitis B and inactivated poliovirus (IPV) components. The vaccines are indicated for active immunization in infants and young children to help prevent these vaccine-preventable diseases
- In 2025, Infanrix/Pediarix generated revenue of $0.7B, representing a 9.38% increase compared to $0.64B in 2024. Growth was primarily driven by higher overall sales across key markets
14. Rotarix
Total Revenue: $0.73B
Company: GSK
First Approved: US (Apr 03, 2008), EU (Feb 21, 2006)
Indications Approved: Rotavirus
- Rotarix is a live attenuated oral vaccine developed to prevent rotavirus gastroenteritis by inducing mucosal and systemic immune responses against rotavirus infections in infants
- The vaccine contains a live attenuated human rotavirus strain of G1P[8] specificity and is indicated for the prevention of gastroenteritis caused by rotavirus in infants, administered as a two-dose oral series during early infancy
- In 2025, Rotarix generated revenue of $0.73B, reflecting a 0.14% decline compared to $0.73B in 2024. The slight decrease was primarily attributed to lower sales in the US, partially offset by stable demand across other international markets
13. Capvaxive
Total Revenue: $0.75B
Company: Merck & Co.
First Approved: US (Jun 17, 2024), EU (Mar 23, 2025)
Indications Approved: Pneumococcal Pneumonia and Invasive Pneumococcal diseases
- Capvaxive is a 21-valent pneumococcal conjugate vaccine (PCV21) developed to prevent invasive pneumococcal disease and pneumococcal pneumonia by inducing T-cell–dependent immune responses through capsular polysaccharides conjugated to the CRM197 carrier protein
- The vaccine provides protection against 21 Streptococcus pneumoniae serotypes selected to address those most commonly associated with invasive disease in adults and is approved for the prevention of pneumococcal disease in adults aged 18 years and older
- In 2025, Capvaxive generated revenue of $0.75B, representing a 733.33% increase compared to $0.09B in 2024. Growth was primarily driven by continued uptake following its US launch in 2024, supported by early commercialization and strong adoption in certain international markets
12. Arexvy
Total Revenue: $0.8B
Company: GSK
First Approved: US (May 03, 2023), EU (Jun 06, 2023)
Indications Approved: LRTD caused by Respiratory Syncytial Virus (RSV)
- Arexvy is an adjuvanted recombinant respiratory syncytial virus (RSV) vaccine developed to prevent lower respiratory tract disease caused by RSV by inducing robust neutralizing antibody and cellular immune responses against the prefusion F glycoprotein of the virus
- The vaccine contains the recombinant RSV prefusion F glycoprotein antigen combined with GSK’s proprietary AS01E adjuvant system and is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older, as well as adults aged 50–59 years who are at increased risk of RSV disease in select markets
- In 2025, Arexvy generated revenue of $0.8B, representing an 8.11% increase compared to $0.74B in 2024. Growth was primarily driven by recommendation and reimbursement in Germany, along with tender deliveries in Spain and Canada, supporting continued expansion of the vaccine across key international markets
11. Vaxneuvance
Total Revenue: $0.82B
Company: Merck & Co.
First Approved: US (July 16, 2021), EU (Dec 13, 2021)
Indications Approved: Pneumococcal Infections
- Vaxneuvance is a 15-valent pneumococcal conjugate vaccine (PCV15) designed to prevent invasive pneumococcal disease and pneumonia by inducing T-cell–dependent immune responses against Streptococcus pneumoniae through capsular polysaccharides conjugated to a carrier protein
- The vaccine provides protection against 15 pneumococcal serotypes—1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F – and is approved for active immunization in infants, children, and adults to help prevent invasive pneumococcal disease caused by these serotypes
- In 2025, Vaxneuvance generated revenue of $0.82B, representing a 2.50% increase compared to $0.8B in 2024. Growth was primarily driven by higher demand in Europe and certain Asia-Pacific markets, partially offset by lower demand in Japan and Latin America due to competitive pressure. In the US, sales remained nearly flat as favorable public and private sector purchasing patterns were offset by increased competition
10. Boostrix
Total Revenue: $0.88B
Company: GSK
First Approved: US (May 03, 2005), EU (Sep 24, 2010)
Indications Approved: Diphtheria, Tetanus, Acellular Pertussis Booster
- Boostrix is a combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine developed to provide booster immunization against tetanus, diphtheria, and pertussis by eliciting protective antibody responses to all three pathogens
- The vaccine contains tetanus toxoid, reduced quantities of diphtheria toxoid, and purified pertussis antigens, including pertussis toxoid, filamentous hemagglutinin, and pertactin, and is indicated as a booster dose for adolescents and adults, including use during pregnancy to help protect newborns against pertussis
- In 2025, Boostrix generated revenue of $0.88B, representing a 3.53% increase compared to $0.85B in 2024. The increase in reported US dollar sales was primarily driven by favourable foreign currency exchange rates, despite lower sales in the US market and a decline in revenue when measured in British pounds.
9. ProQuad
Total Revenue: $0.93B
Company: Merck & Co.
First Approved: US (Sep 06, 2005), EU (Apr 05, 2006)
Indications Approved: Measles, Mumps, Rubella, Varicella
- ProQuad is a live attenuated combination vaccine developed to protect against four viral diseases—measles, mumps, rubella, and varicella (MMRV) – by inducing humoral and cellular immune responses against each of the vaccine antigens
- The vaccine combines the attenuated strains used in measles, mumps, and rubella vaccines with the Oka/Merck strain of varicella-zoster virus and is indicated for active immunization against measles, mumps, rubella, and chickenpox in children aged 12 months through 12 years
- In 2025, ProQuad generated revenue of $0.93B, representing a 1.09% increase compared to $0.92B in 2024. Growth was primarily driven by higher demand in Europe, partially offset by lower sales in the US due to reduced demand, which was partly mitigated by higher net pricing
8. Abrysvo
Total Revenue: $1.03B
Company: Pfizer
First Approved: US (May 31, 2023), EU (Aug 23, 2023)
Indications Approved: LRTD and severe LRTD caused by RSV
- Abrysvo is a bivalent recombinant respiratory syncytial virus (RSV) vaccine developed to prevent lower respiratory tract disease caused by RSV by inducing neutralizing antibodies against the prefusion F glycoproteins of both RSV A and RSV B subtypes
- The vaccine is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older, adults aged 18–59 years at increased risk of severe disease, and for maternal immunization during pregnancy to protect infants from birth through six months of age
- In 2025, Abrysvo generated revenue of $1.03B, representing a 37.33% increase compared to $0.75B in 2024. Growth was primarily driven by strong launch uptake of both the adult and maternal indications in certain international markets, increased market share in the adult indication, and higher demand for the maternal indication in the US, partially offset by lower vaccination rates among older adults following updated ACIP recommendations in the US
7. Varivax
Total Revenue: $1.04B
Company: Merck & Co.
First Approved: US (Mar 17, 1995), EU (Apr 21, 2021)
Indications Approved: Active Immunization of Varicella (Chickenpox)
- Varivax is a live attenuated varicella vaccine developed to prevent chickenpox (varicella) by inducing protective humoral and cellular immune responses against the varicella-zoster virus (VZV)
- The vaccine contains the live attenuated Oka/Merck strain of varicella-zoster virus and is indicated for active immunization against varicella in children, adolescents, and adults who are susceptible to chickenpox
- In 2025, Varivax generated revenue of $1.04B, reflecting a 5.45% decline compared to $1.10B in 2024. The decrease was primarily driven by the unfavorable impact of CDC Pediatric Vaccine Stockpile activity and lower demand in the Asia-Pacific region, partially offset by higher demand in Latin America during the year
6. Bexsero
Total Revenue: $1.61B
Company: GSK
First Approved: US (Jan 23, 2015), EU (Jan 14, 2013)
Indications Approved: Meningitis
- Bexsero is a multicomponent recombinant vaccine developed to prevent invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B by inducing bactericidal antibodies against multiple meningococcal antigens
- The vaccine contains four antigenic components – factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA), and outer membrane vesicles (OMVs) containing PorA P1.4 – and is approved for active immunization against meningococcal group B disease across infants, children, adolescents, and adults in multiple countries
- In 2025, Bexsero generated revenue of $1.61B, representing a 20.15% increase compared to $1.34B in 2024. Growth was primarily driven by recommendations and reimbursement in Germany, expanded cohort recommendations in France, and strong commercial execution in Turkey and Vietnam, with further expansion expected through broader geographic reach and additional eligible populations.
5. Spikevax (mRNA-1273) & mNEXSPIKE (COVID)
Total Revenue: $1.81B
Company: Moderna
First Approved: Spikevax: US (Aug 23, 2021), EU (Oct 10, 2022); mNEXSPIKE: US (May 30, 2025), EU (Feb 12, 2026)
Indications Approved: COVID-19
- Spikevax (mRNA-1273) and mNEXSPIKE are mRNA-based vaccines developed to prevent COVID-19 by encoding the SARS-CoV-2 spike protein, thereby stimulating robust neutralizing antibody and T-cell immune responses against the virus
- Spikevax is approved for the prevention of COVID-19 across multiple age groups, while mNEXSPIKE is Moderna’s next-generation COVID-19 vaccine designed to provide broader and more durable protection with a lower antigen dose and improved immune response
- In 2025, Spikevax and mNEXSPIKE generated revenue of $1.81B, representing a 41.61% decline compared to $3.1B in 2024. The decrease was primarily attributed to lower global demand for COVID-19 vaccines, reduced vaccination rates in key markets, and the continued transition from pandemic-driven vaccination campaigns to seasonal immunization strategies.
4. Comirnaty
Total Revenue: $4.36B
Company: Pfizer, BioNTech
First Approved: US (Aug 23, 2021), EU (Oct 10, 2022)
Indications Approved: COVID-19
- Comirnaty is an mRNA-based vaccine developed to prevent coronavirus disease 2019 (COVID-19) by encoding the SARS-CoV-2 spike protein, thereby eliciting robust humoral and cellular immune responses
- The vaccine is approved for the prevention of COVID-19 across multiple age groups and has been updated periodically to target emerging SARS-CoV-2 variants, helping protect against symptomatic infection and severe disease
- In 2025, Comirnaty generated revenue of $4.36B, reflecting an 18.50% decline compared to $5.35B in 2024. The decrease was primarily driven by lower contractual deliveries and reduced vaccination rates in certain international markets, as well as lower utilization in the US following narrower vaccination recommendations, partially offset by lower product returns and increased market share in the US
3. Shingrix
Total Revenue: $4.85B
Company: GSK
First Approved: US (Mar 21, 2018), EU (Oct 20, 2017)
Indications Approved: Herpes Zoster (Shingles)
- Shingrix is a recombinant, adjuvanted vaccine developed to prevent herpes zoster (shingles) and its complications by eliciting a strong antigen-specific cellular and humoral immune response against the varicella-zoster virus glycoprotein E antigen
- The vaccine is approved for the prevention of shingles and postherpetic neuralgia in adults aged 50 years and older, as well as in adults aged 18 years and older who are at increased risk of herpes zoster due to immunodeficiency or immunosuppression
- In 2025, Shingrix generated revenue of $4.85B, representing a 13.58% increase compared to $4.27B in 2024. Growth was primarily driven by strong demand in international markets, partially offset by lower demand in the US
2. Gardasil & Gardasil-9
Total Revenue: $5.23B
Company: Merck & Co.
First Approved: US (Gardasil-Jun 06, 2006; Gardasil-9- Dec 10, 2014), EU (Gardasil- Sep 20, 2006; Gardasil-9- Jun 10, 2015)
Indications Approved: Gardasil – Human Papillomavirus Vaccines and Gardasil-9 – Human Papill
- Gardasil and Gardasil 9 are recombinant human papillomavirus (HPV) vaccines designed to prevent HPV-related cancers and diseases by inducing neutralising antibodies against specific HPV types through virus-like particles (VLPs)
- Gardasil provides protection against four HPV types (6, 11, 16, and 18), while Gardasil 9 expands coverage to nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58), helping prevent cervical, vulvar, vaginal, anal, and certain head and neck cancers, as well as genital warts
- In 2025, Gardasil and Gardasil 9 generated revenue of $5.23B, reflecting a 39.04% decline compared to $8.58B in 2024. The decrease was primarily attributed to significantly lower sales in China, where reduced demand for Gardasil/Gardasil 9 led to a substantial decline in Merck’s business, with sales expected to remain subdued through 2026
1. Prevnar Family
Total Revenue: $6.49B
Company: Pfizer, Daewoong
First Approved: US (Prevnar 13: Feb 24, 2010; Prevnar 20: Jun 08, 2021), EU (Prevnar 13: Feb 14, 2022; Prevnar 20: Dec 09, 2009)
Indications Approved: Pneumococcal Disease Prophylaxis
- The Prevnar Family comprises Prevnar 13 and Prevnar 20, both pneumococcal conjugate vaccines that induce T-cell–dependent immune responses through capsular polysaccharides conjugated to carrier proteins
- Prevnar 13 provides protection against 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), while Prevnar 20 expands coverage to 20 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), offering protection against invasive pneumococcal disease and pneumonia across pediatric and adult populations
- In 2025, the Prevnar Family generated revenue of $6.49B, reflecting a 1.25% increase compared to $6.41B in 2024. Growth was primarily driven by strong uptake of the adult indication in the US following the CDC recommendation for adults aged 50-64 years, increased adoption in certain international markets, and pediatric launches in emerging markets, partially offset by lower pediatric sales, shipment timing in the US, and competitive pressure in select international markets
Criteria:
- The report is based on vaccine revenue generated between January and December 2025, including revenues from individual vaccines and vaccine franchises
- For companies with non-December fiscal year endings, revenue has been calculated for the January–December 2025 period using quarterly and annual financial filings. Where vaccine-specific sales were not disclosed, estimates were derived from publicly available company reports and credible secondary sources
- Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency across all rankings
Source:
- Company Websites
- Press Releases
- Annual Reports
- Quarterly Reports
- Google Finance
- OANDA
Related Post: Top 20 Vaccines of 2025